|
|
Vaccine Detail
|
ALVAC-CEA Vaccine |
| Vaccine Information |
- Vaccine Name: ALVAC-CEA Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007244
- Type: Other
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: CEA
- CEACAM5 (CEA)
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: A recombinant ALVAC-CEA is used to induce CEA-specific cytotoxic T-cell responses. The vaccination combines with a triad of costimulatory molecules (B7.1, ICAM-1, and LFA-3) has also stimulated significant T-cell increases.(Marshall, 2003).
- Description: A cancer vaccine consisting of ALVAC, a highly attenuated poxvirus strain derived from the canarypox virus, encoding for the tumor associated antigen (TAA) carcinoembryonic antigen (CEA), with potential antineoplastic activity. Upon administration, ALVAC-CEA vaccine expresses CEA and may stimulate a host immune response against tumor cells expressing CEA. This may result in the inhibition of tumor growth and/or metastasis. CEA is overexpressed in a variety of tumor cell types. (NCIT_C1648).
|
| Host Response |
|
|
| References |
Marshall, 2003: Marshall J. Carcinoembryonic antigen-based vaccines. Seminars in oncology. 2003; 30(3 Suppl 8); 30-36. [PubMed: 12881810].
NCIT_C1648: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1648]
|
|
